Home

25Apr 2017

Following the recent announcement by PM Narendra Modi hinting at a legal framework for doctors to prescribe generic medicines cheaper than equivalent branded generic drugs, doctors appeared to welcome the move and opined that it will benefit patients as the life-saving drugs could be obtained at much cheaper rates. (1,2) In reality, India being the […]

10Apr 2017

Bioresorbable stents have effectively been pulled from the European market by Abbott and will now be available only in “clinical registry setting at select sites/institutions” in Europe, where they will be monitored till a review in 2018. India has been among the largest markets for these stents in recent years. The development comes in the […]

31Mar 2017

According to the World Health Organization (W.H.O), there is currently no universally agreed definition among its member states in what is widely known as ‘Counterfeit medicines’. Nevertheless, W.H.O does indicate that the term ‘counterfeit’ is widely used to include falsified, unlicensed, falsely packaged, stolen and substandard medical products. Jurisdictions across the world define counterfeit medicines […]

19Mar 2017

Healthcare decision making is usually characterized by a low degree of transparency. The demand for transparent decision processes can be fulfilled only when assessment, appraisal and decisions about health technologies are performed under a systematic construct of benefit assessment. The benefit of an intervention is often multidimensional and, thus, must be represented by several decision […]

06Mar 2017

Clinical research includes the traditional prospective clinical trials, cohort studies, and case-control studies, while outcomes research (OR) has now solidified itself as a separate class of clinical research. OR is an evolving and critical part of health sciences research due to its focus on the improvement of patient care in the practice setting. Evidence included […]

07Feb 2017

In many parts of the world, the value of medicines is measured by a unit called ‘Quality-Adjusted Life Year’ (QALY), a metric that health economists and others use to quantify the health benefits generated by a particular treatment. QALYs are often used by state-run health systems in many countries to help decide which drugs to […]

04Feb 2017

The fifth and last union budget for the present term of the BJP government focuses mainly on agriculture and rural economy. Besides, this budget  is also promoting education and health (1). Healthcare demands a national priority status and requires allocation of more funds to deliver affordable and quality healthcare services to all. Health budget was […]

30Jan 2017

The purpose of medicines is to improve patients’ lives. Despite the increasing number and scope of patient involvement initiatives, there is no accepted master framework for systematic patient involvement in pharma-led medicines development. Patient engagement is more productive, but inconsistent and fragmented on a broader level. Incorporating the patient perspective in healthcare research is strongly […]

24Nov 2016

While scientists, clinicians, and regulators play critical roles in understanding and communicating the benefits and risks of drugs/medical treatments, only patients live with their medical conditions and make choices regarding their personal care. They provide a unique voice and unique perspective. In recent years, more and more studies are focusing on patient reported outcomes (PROs). […]